Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Allena Pharmaceuticals's 3-Year RORE % for the quarter that ended in Jun. 2022 was 0.00%.
The industry rank for Allena Pharmaceuticals's 3-Year RORE % or its related term are showing as below:
ALNAQ's 3-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -5.96 * Ranked among companies with meaningful 3-Year RORE % only.
Allena Pharmaceuticals 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Allena Pharmaceuticals's 3-Year RORE %
For the Biotechnology subindustry, Allena Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allena Pharmaceuticals's 3-Year RORE % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Allena Pharmaceuticals's 3-Year RORE % falls into.
Allena Pharmaceuticals 3-Year RORE % Calculation
Allena Pharmaceuticals's 3-Year RORE % for the quarter that ended in Jun. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2022 and 3-year before.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Allena Pharmaceuticals 3-Year RORE % Related Terms
Thank you for viewing the detailed overview of Allena Pharmaceuticals's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALNAQ has been successfully added to your 